Leung and Stubbs’ diverse professional backgrounds position them to help advance DRIF’s mission to find a cure for diabetes
MIAMI, FL – January 12, 2022 – The Diabetes Research Institute Foundation (DRIF) recently appointed Scarlett Leung, CEO and co-founder of Sugarbreak, and Matthew Stubbs, managing partner at Duncan Stubbs, PLLC, to its national board of directors. Leung and Stubbs join the board with a wide range of leadership, executive and personal experiences in the diabetes community; making them well-poised to guide DRIF’s organizational goals.
“DRIF’s mission of finding the cure for diabetes now is made possible in large part by the unparalleled leadership and expertise of our board members,” said William Fishlinger, chairman, DRIF National Board of Directors. “We are eager to begin working alongside Scarlett and Matthew and are confident that they will be instrumental in shaping the future of DRIF.”
Leung, a successful entrepreneur, first developed her passion for supporting the diabetes community after witnessing a close friend struggle with type 1 diabetes. Leung was inspired to create an end-to-end solution for blood sugar management and, today, she is CEO and co-founder of Sugarbreak, a company that focuses on finding a natural and accessible solution to better manage blood sugar. Prior to creating her own company, Leung has successfully led fashion, grocery, and fertility businesses with the common focus of a consumer-oriented vision.
“Being appointed to the Diabetes Research Institute Foundation’s National Board of Directors is an honor and I am eager to work with the talented women and men at DRIF,” said Scarlett Leung, CEO and co-founder of Sugarbreak. “This cause is personal to me and the mission of DRIF also aligns with my professional passion of providing solutions to those who struggle with diabetes.”
Matthew Stubbs brings more than a decade of legal experience to the board. He is currently the managing partner at national law firm Duncan Stubbs, PLLC, where he provides counsel for individuals harmed by pharmaceutical drugs, medical devices and consumer products. Matthew has lived with type 1 diabetes since he was 12 years old and he’s motivated to support finding a cure for diabetes so that others like him can experience full health.
“I am honored to be appointed to the national board of directors of an organization whose mission is so meaningful to me,” said Matthew Stubbs, managing partner at Duncan Stubbs, PLLC. “This appointment represents the opportunity to make significant change in the lives of those impacted by diabetes.”
Leung and Stubbs appointments took effect on January 1, 2022 through June 20, 2023 term.
# # #
About the Diabetes Research Institute (DRI) and Foundation
The Diabetes Research Institute (DRI) and Foundation were created for one reason – to cure diabetes – which is and will continue to be the singular focus until that goal is reached. As one of the largest and most comprehensive research centers dedicated to curing diabetes, the DRI is working to restore natural insulin production and normalize blood sugar levels without imposing other risks. Researchers have already shown that transplanted insulin-producing islet cells allow people with type 1 diabetes to live without the need for insulin injections. Some of the DRI’s islet transplant patients have been free from insulin for more than 10 years. Funding provided by the Foundation is the driving force that allows DRI scientists to pursue new and innovative ideas, and to speed these discoveries to patients. The Diabetes Research Institute Foundation is the organization of choice for those who want to Be Part of the Cure. For more information, please visit DiabetesResearch.org or call 800-321-3437.